Telmisartan, ramipril, or both in patients at high risk for vascular events.

Yusuf, Salim;Teo, Koon K;Pogue, Janice;Dyal, Leanne;Laloux, Patrice;et.al.
(2008) New England Journal of Medicine — Vol. 358, n° 15, p. 1547-1559 (2008)

Files

OntargetInvestigators-NEJM-2008.pdf
  • Restricted Access
  • Adobe PDF
  • 482.87 KB
Request a copy

Details

Authors
  • Yusuf, Salim
    Author
  • Teo, Koon K
    Author
  • Pogue, Janice
    Author
  • Dyal, Leanne
    Author
  • Laloux, PatriceUCLouvain
    Collaborator
Show more
Abstract
Telmisartan was equivalent to ramipril in patients with vascular disease or high-risk diabetes and was associated with less angioedema. The combination of the two drugs was associated with more adverse events without an increase in benefit. (ClinicalTrials.gov number, NCT00153101 [ClinicalTrials.gov].).
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Yusuf, S., Teo, K. K., Pogue, J., Dyal, L., Copland, I., Schumacher, H., Dagenais, G., Sleight, P., & Anderson, C. (2008). Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine, 358(15), 1547-1559. https://doi.org/10.1056/NEJMoa0801317 (Original work published 2008)